The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2020 | Prognosis and treatment in high-risk MDS
Drorit Merkel
• 5 Mar 2020
Drorit Merkel, MD, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel, discusses the unmet need for novel treatments in high-risk myelodysplastic syndromes (MDS), with reference to the advantages and disadvantages of using azacitidine. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
